Overall rank by patents
#2,834
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Taiho Pharmaceutical Co., Ltd.
USPTO PatentsView assignee record - 136 granted patents across 16 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
136
Total patents granted
16
CPC technology areas
14.0
Avg claims per patent
-23%
5-year filing velocity
The verdict
Taiho holds 136 US patents across 16 technology areas, rank #2,834 of 50,000 tracked assignees.
- #2,834
- of 50,000 US assignees by volume
- Top 29%
- by Innovation Score (43.2/100)
- 14.0
- avg claims per patent
- -23%
- filing velocity, last 5 yrs
Portfolio overview
Taiho Pharmaceutical Co., Ltd. has been granted 136 US utility patents between 2015 and 2025, placing Taiho Pharmaceutical Co., Ltd. at rank #2,834 across all assignees tracked by PlainPatent. This portfolio spans 16 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.0 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Taiho Pharmaceutical Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Taiho sits between Shell USA, Inc. (136 patents, rank #2,830) and Freni Brembo S.p.a. (135 patents, rank #2,838) - the closest US assignees by grant volume. The composite Innovation Score of 43.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 59 grants, compared with 77 in the 2015–2019 window, a -23% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Taiho Pharmaceutical Co., Ltd.'s 14.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 16 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Taiho Pharmaceutical Co., Ltd. against peers pursuing similar technology classes.
Who files at Taiho's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Shell USA
SHELL USA, INC.
136 patents
- SK Chemicals
SK Chemicals CO., Ltd.
136 patents
- Syracuse Universi…
SYRACUSE UNIVERSITY
136 patents
- Sion Power
Sion Power Corporation
136 patents
- Taiho Pharmaceuti… ◀
Taiho Pharmaceutical Co., Ltd.
136 patents
- Baylor University
Baylor University
135 patents
- Chemocentryx
CHEMOCENTRYX, INC.
135 patents
- Forum US
FORUM US, INC.
135 patents
- Freni Brembo S P A
FRENI BREMBO S.P.A.
135 patents
What this shows Taiho holds 136 patents at rank #2,834, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Taiho
By rank, the assignees closest to #2,834 in granted patent volume.
- Shell USA, Inc. #2,830 · 136 patents
- SK Chemicals Co., Ltd. #2,831 · 136 patents
- Syracuse University #2,832 · 136 patents
- Sion Power Corporation #2,833 · 136 patents
- Baylor University #2,835 · 135 patents
- Chemocentryx, Inc. #2,836 · 135 patents
- Forum US, Inc. #2,837 · 135 patents
- Freni Brembo S.p.a. #2,838 · 135 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Taiho's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Taiho's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
43 Top 29% higher than 71% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 12 | 8.8% |
| 2016 | 10 | 7.4% |
| 2017 | 20 | 14.7% |
| 2018 | 17 | 12.5% |
| 2019 | 18 | 13.2% |
| 2020 | 11 | 8.1% |
| 2021 | 15 | 11.0% |
| 2022 | 6 | 4.4% |
| 2023 | 8 | 5.9% |
| 2024 | 10 | 7.4% |
| 2025 | 9 | 6.6% |
Which technologies does Taiho Pharmaceutical Co., Ltd. patent most?
Top 15 of 16 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Taiho Pharmaceutical Co., Ltd. hold?
Taiho Pharmaceutical Co., Ltd. holds 136 US granted patents filed between 2015 and 2025, spanning 16 technology areas.
What is Taiho Pharmaceutical Co., Ltd.'s Innovation Score?
Taiho Pharmaceutical Co., Ltd. has an Innovation Score of 43.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Taiho Pharmaceutical Co., Ltd. focus on?
Taiho Pharmaceutical Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 116 patents. The company has filed patents in 16 CPC subclasses total.
Is Taiho Pharmaceutical Co., Ltd.'s patent filing rate increasing or decreasing?
Taiho Pharmaceutical Co., Ltd.'s recent filing velocity is -23% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Taiho Pharmaceutical Co., Ltd.'s patents?
Taiho Pharmaceutical Co., Ltd.'s patents average 14.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Taiho Pharmaceutical Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Taiho's 136 grants land it in the top 29% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Taiho ranks #2,834 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.